Table 4.

Survival analyses according to mutational status through different techniques in the anti-EGFR cohort

CobasTherascreenHighly sensitive dPCR qualitative detectionHighly sensitive dPCR cutoff 1%
mutwtmutwtmutwtmutwt
28226302255619840214
KRAS (exon 2)PFS monthsMedian (mut/wt)3.887.033.887.035.227.034.867.03
HR (95% CI)1.79 (1.12–2.85)1.44 (0.92–2.25)1.29 (0.91–1.82)1.51 (1.02–2.24)
P0.0150.1130.1570.041
OS monthsMedian (mut/wt)12.5518.1712.5518.113.818.113.318.1
HR (95% CI)2.06 (1.27–3.34)1.38 (0.87–2.18)1.52 (1.04–2.22)1.76 (1.14–2.72)
P0.0030.1670.0310.011
701847218310115282172
RAS (KRAS ex 2/3/4 + NRAS ex 2/3/4)PFS monthsMedian (mut/wt)4.737.194.737.195.227.24.867.2
HR (95% CI)1.21 (0.87–1.67)1.37 (0.989–1.896)1.34 (0.99–1.8)1.53 (1.12–2.09)
P0.2530.0590.0510.007
OS monthsMedian (mut/wt)13.6418.712.5919.0613.2718.714.8918.4
HR (95% CI)1.72 (1.23–2.40)1.71 (1.22–2.39)1.61 (1.16–2.23)1.9 (1.33–2.72)
P0.0020.0020.0040.0004
821729116411513997157
RAS + BRAFPFS monthsMedian (mut/wt)4.437.494.437.625.197.594.387.59
HR, (95% CI)1.50 (1.11–2.04)1.87 (1.37–2.53)1.54 (1.15–2.05)1.66 (1.23–2.24)
P0.009≤0.0010.0030.0008
OS monthsMedian (mut/wt)13.2719.1912.5520.2413.820.0113.6719.72
HR (95% CI)1.86 (1.34–2.58)1.90 (1.38–2.62)1.72 (1.25 -2.39)2.01 (1.41–2.85)
P≤0.001≤0.0010.0010.0001
  • NOTE: Adjusted for age, gender, and chemotherapy lines.

  • Abbreviations: wt, wild-type tumor; mut, mutated tumor.